LIPOSORBER LA-15 System
Kaneka Pharma America Corp. · Decision date Jun 16, 2026
What did the FDA decide?
FDA records P910018/S042 as a supplement to PMA P910018, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jun 16, 2026.
FDA approval order statement
a change in the acceptance criterion for the opening torque test performed during in-process inspection of the SULFLUX KP-05 filter the of LIPOSORBER LA-15 System
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Jun 16, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P910018/S042
- Regulatory pathway
- PMA supplement
- Applicant
- Kaneka Pharma America Corp.
- Product code
- MMY
- Decision code
- OK30
- Decision date
- Jun 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Lipoprotein, low density, removal.
- Applicant
- Kaneka Pharma America Corp.
- Product code
- MMY
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P910018/S041 · Related supplement
LIPOSORBER LA-15 System
P910018/S042 received
Application receipt date recorded by FDA.
P910018/S042 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P910018. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P910018
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
LIPOSORBER LA-15 SystemP910018/S041 | Kaneka Pharma America Corp. | PMA supplement | Mar 30, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Kaneka Pharma America Corp.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 546 Fifth Ave., 21st Floor, New York, NY, 10036
Sources and methodology
- Original FDA record: P910018/S042
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records